Vasculogenic Mimicry in Urothelial Carcinoma
Study Details
Study Description
Brief Summary
In this study, the investigators aim at:
-
Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double staining.
-
Correlate the presence of vasculogenic mimicry with the clinicopathologic features as age, sex, TNM stage, pathological grade, recurrence, carcinoma in situ, lymphovascular emboli, lymph node metastasis, necrosis, surgical margin, multifocality and tumor size in urothelial carcinoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Bladder cancer is the ninth most common cancer worldwide which seriously affects human health. In Egypt, it is the third common malignant tumor.
Urothelial carcinoma (UC) is considered the most common histologic type of bladder cancer.
It is well recognized that the biological behavior of several cancers is closely related to their blood supply. Tumor progression and metastasis have been long associated with tumor angiogenesis. However, several studies demonstrated that vascular targeting drugs which induce endothelial cell apoptosis have a little effect. So, it has been suggested that novel tumor microcirculation patterns may exist in these neoplasms.
Vasculogenic mimicry (VM), is a novel tumor microcirculation system. Maniotis et al initially discovered VM in melanoma and defined these channels to be composed of tumor basement membrane lined externally by tumor cells, lacking blood vessel endothelium and containing plasma and red blood cells. So VM can be distinguished using immunohistochemical (IHC) staining and histochemical double staining. VM is CD31- or CD34-negative (endothelial markers) and periodic acid-Schiff (PAS) positive.
Vasculogenic mimicry was detected in several malignant tumors. Several studies reported that VM can promote tumor progression and metastasis and it is positively associated with pathological grade, stage, recurrence and drug resistance. Previous studies which evaluate, the role of VM in urothelial carcinoma yield controversial results. So, the value of VM in urothelial carcinomas and its relation to the clinicopathologic parameters remains to be elucidated.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| 1 presence of recurrence of urothelial carcinoma |
Other: formalin fixed paraffin embedded blocks
The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
|
| 2 absence of recurrence of urothelial carcinoma |
Other: formalin fixed paraffin embedded blocks
The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
|
Outcome Measures
Primary Outcome Measures
- Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double staining [baseline]
Secondary Outcome Measures
- Correlate the presence of vasculogenic mimicry with the clinicopathologic features in urothelial carcinoma. [baseline]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
- Specimens of urothelial carcinoma.
Exclusion Criteria:
-
- Any criteria that not fulfill the inclusion criteria such as resected urinary bladder tumors other than urothelial carcinoma.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
- Principal Investigator: Abeer R Mohamed, professor, Assiut University
Study Documents (Full-Text)
None provided.More Information
Publications
- Aso Y, Ushiyama T, Suzuki K, Tajima A, Naide Y, Ohshima S, Matsuura O, Fukushima M, Ota K, Ono Y, et al. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract]. Nihon Gan Chiryo Gakkai Shi. 1988 May 20;23(5):1046-51. Japanese.
- Zhou L, Chang Y, Xu L, Hoang ST, Liu Z, Fu Q, Lin Z, Xu J. Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy. Oncotarget. 2016 Nov 15;7(46):76214-76223. doi: 10.18632/oncotarget.12775.
- VM in urothelial carcinoma